Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reaction-ligase detection reaction

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 6, 2011, Pages 560-566

  Wang, Yong Zhong ^a   Xiao, Jun Hua ^b   Liu, Long Gen ^a   Ye, Chun Yan ^a   Shen, Hong Yu ^a   Xu, Tian Min ^a   Zhu, Ke Zhuan ^a  

^a The Third People's Hospital of Changzhou   (China)

^b DONGHUA UNIVERSITY   (China)

Author keywords

Drug resistance; Genotype; Hepatitis B; Mutation

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TELBIVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL DECISION MAKING; CODON; CONTROLLED STUDY; DNA EXTRACTION; ELECTROPHORESIS; GENOTYPING TECHNIQUE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION LIGASE DETECTION REACTION; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TIME; VIRUS DETECTION; VIRUS GENOME; VIRUS MUTANT; WILD TYPE;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIGASE CHAIN REACTION; MICROBIAL SENSITIVITY TESTS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES;

EID: 84862950530     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70251-3     Document Type: Article

References (30)

1. Alazawi W., Foster G.R. Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis 2008, 21:508-515.
2. Kao J.H., Wu N.H., Chen P.J., et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000, 33:998-1002.
3. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in comination with lamivudine for HbeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
4. Lok A.S., Zoulim F., Locarnini S. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254-265.
5. Fung S.K., Lok A.S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?. Hepatology 2004, 40:790-792.
6. Norder H., Courouce A.M., Coursaget P., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47:289-309.
7. Wai C.T., Chu C.J., Hussain M., et al. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002, 36:1425-1430.
8. Erhardt A., Blondin D., Hauck K., et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005, 54:1009-1013.
9. Cooksley W.G. Do we need to determine viral genotype in treating chronic hepatitis B?. J Viral Hepat 2010, 17:601-610.
10. Ferreira P.R., Tenore S.D. Response predictors to treatment with pegylated interferon in chronic hepatitis B. Braz J Infect Dis 2010, 14:519-525.
11. Walsh A.W., Langley D.R., Colonno R.J., et al. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PloS One 2010, 5:e9195.
12. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998, 27:1670-1677. Lamivudine Clinical Investigation Group.
13. Gauthier J., Bourne E.J., Lutz M.W., et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999, 180:1757-1762.
14. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004, 19:1276-1282.
15. Stuyver L., Van Geyt C., De Gendt S., et al. Line probe assay for monitoring drug resistance in hepatitis B virus infected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707.
16. Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
17. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673-2681.
18. Lee Y.S., Suh D.J., Lim Y.S., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43:1385-1391.
19. Liang X., Bi S., Yang W., et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis b vaccination. Vaccine 2009, 27:6550-6557.
20. Pas S.D., de Man R.A., Fries E., et al. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridization. J Clin Virol 2002, 25:63-71.
21. Hussain M., Fung S., Libbrecht E., et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006, 44:1094-1097.
22. Niesters H.G., Zoulim F., Pichoud C., et al. Validation of the INNO- LiPA HBV DR assay (version 2) in Monitoring hepatitis B virus-infected patients receiving mucleoside analog treatment. Antimicrob Agents Chemother 2010, 54:1283-1289.
23. Xiao Z., Xiao J., Jiang Y., et al. A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. Hepatol Res 2006, 34:150-155.
24. Wang Y.Z., Xiao J.H., Ruan L.H., et al. Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clin Chim Act 2009, 408:70-74.
25. Shi M., Zhang Y., Zhu Y.H., et al. Comparison of real-time PCR with the Cobas Amplicor for quantitation of hepatitis B virus DNA in serum samples. World J Gastroenterol 2008, 14:479-483.
26. Degertekin B., Hussain M., Tan J., et al. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 2009, 49:695-701.
27. Lee H.C., Suh D.J., Ryu S.H., et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconverson. Gut 2003, 52:1779-1783.
28. Wang Z., Huang Y., Wen S., et al. Hepatitis B virus genotypes and subgenotypes in China. Hepatol Res 2007, 37(S1):S36-S41.
29. Yim H.J., Hussain M., Liu Y., et al. Evolution of multi-drug resistant hepatitis b virus during sequential therapy. Hepatology 2006, 44:703-712.
30. Locarnini S. Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008, 2:147-151.